Form 8-K

8-K — Perspective Therapeutics, Inc.

Accession: 0001193125-26-216777

Filed: 2026-05-11

Period: 2026-05-11

CIK: 0000728387

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — catx-20260511.htm (Primary)

EX-99.1 (catx-ex99_1.htm)

EX-99.2 (catx-ex99_2.htm)

GRAPHIC (img236230851_0.jpg)

GRAPHIC (catx-ex99_2s1.jpg)

GRAPHIC (catx-ex99_2s2.jpg)

GRAPHIC (catx-ex99_2s3.jpg)

GRAPHIC (catx-ex99_2s4.jpg)

GRAPHIC (catx-ex99_2s5.jpg)

GRAPHIC (catx-ex99_2s6.jpg)

GRAPHIC (catx-ex99_2s7.jpg)

GRAPHIC (catx-ex99_2s8.jpg)

GRAPHIC (catx-ex99_2s9.jpg)

GRAPHIC (catx-ex99_2s10.jpg)

GRAPHIC (catx-ex99_2s11.jpg)

GRAPHIC (catx-ex99_2s12.jpg)

GRAPHIC (catx-ex99_2s13.jpg)

GRAPHIC (catx-ex99_2s14.jpg)

GRAPHIC (catx-ex99_2s15.jpg)

GRAPHIC (catx-ex99_2s16.jpg)

GRAPHIC (catx-ex99_2s17.jpg)

GRAPHIC (catx-ex99_2s18.jpg)

GRAPHIC (catx-ex99_2s19.jpg)

GRAPHIC (catx-ex99_2s20.jpg)

GRAPHIC (catx-ex99_2s21.jpg)

GRAPHIC (catx-ex99_2s22.jpg)

GRAPHIC (catx-ex99_2s23.jpg)

GRAPHIC (catx-ex99_2s24.jpg)

GRAPHIC (catx-ex99_2s25.jpg)

GRAPHIC (catx-ex99_2s26.jpg)

GRAPHIC (catx-ex99_2s27.jpg)

GRAPHIC (catx-ex99_2s28.jpg)

GRAPHIC (catx-ex99_2s29.jpg)

GRAPHIC (catx-ex99_2s30.jpg)

GRAPHIC (catx-ex99_2s31.jpg)

GRAPHIC (catx-ex99_2s32.jpg)

GRAPHIC (catx-ex99_2s33.jpg)

GRAPHIC (catx-ex99_2s34.jpg)

GRAPHIC (catx-ex99_2s35.jpg)

GRAPHIC (catx-ex99_2s36.jpg)

GRAPHIC (catx-ex99_2s37.jpg)

GRAPHIC (catx-ex99_2s38.jpg)

GRAPHIC (catx-ex99_2s39.jpg)

GRAPHIC (catx-ex99_2s40.jpg)

GRAPHIC (catx-ex99_2s41.jpg)

GRAPHIC (catx-ex99_2s42.jpg)

GRAPHIC (catx-ex99_2s43.jpg)

GRAPHIC (catx-ex99_2s44.jpg)

GRAPHIC (catx-ex99_2s45.jpg)

GRAPHIC (catx-ex99_2s46.jpg)

GRAPHIC (catx-ex99_2s47.jpg)

GRAPHIC (catx-ex99_2s48.jpg)

GRAPHIC (catx-ex99_2s49.jpg)

GRAPHIC (catx-ex99_2s50.jpg)

GRAPHIC (catx-ex99_2s51.jpg)

GRAPHIC (catx-ex99_2s52.jpg)

GRAPHIC (catx-ex99_2s53.jpg)

GRAPHIC (catx-ex99_2s54.jpg)

GRAPHIC (catx-ex99_2s55.jpg)

GRAPHIC (catx-ex99_2s56.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: catx-20260511.htm · Sequence: 1

8-K

0000728387false00007283872026-05-112026-05-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-33407

41-1458152

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

c/o Perspective Therapeutics, Inc.

2401 Elliott Avenue

Suite 320

Seattle, Washington

98121

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

CATX

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 11, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated by reference into this Item 2.02.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

Also on May 11, 2026, the Company posted an updated corporate presentation on its website at www.perspectivetherapeutics.com. A copy of the presentation is filed as Exhibit 99.2 to this Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1

Press release issued by Perspective Therapeutics, Inc., dated May 11, 2026.

99.2

Corporate presentation.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PERSPECTIVE THERAPEUTICS, INC.

Date:

May 11, 2026

By:

/s/ Joel Sendek

Joel Sendek

Chief Financial Officer

EX-99.1

Filename: catx-ex99_1.htm · Sequence: 2

EX-99.1

Perspective Therapeutics Provides Recent Business Highlights and

Reports 1Q 2026 Results

•

Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability

•

Three clinical-stage oncology programs advancing across neuroendocrine tumors, melanoma and FAP-positive solid tumors with multiple clinical catalysts expected in 2026 across VMT-α-NET, VMT01 and PSV359 programs; lead program, VMT-α-NET, advancing toward a registration‑enabling study

•

Regional manufacturing network designed to support reliable supply of ready-to-administer radiopharmaceuticals for clinical development and potential commercialization; Chicago site expected to complete construction in 2026

•

Cash runway expected into late 2027 to support planned clinical milestones and operational investments; cash, cash equivalents, and short-term investments of approximately $271M as of March 31, 2026

SEATTLE – May 11, 2026 – Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2026.

“The first quarter of 2026 was marked by continued execution across our clinical programs and strengthening of our financial position,” said Thijs Spoor, Perspective’s CEO. “Our focus on engineering the alpha advantage across every part of the radiopharmaceutical value chain - from the radioisotope to optimized structural chemistry, theranostic processes, and regional manufacturing - differentiates Perspective, and we look forward to providing clinical and manufacturing updates throughout 2026.”

Clinical Highlights

VMT-α-NET

We are conducting a multi-center, open-label, dose-finding study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT).

•

Updated interim data from the study, as of a data cut-off (DCO) date of March 4, 2026, were presented at the American Association for Cancer Research Annual Meeting 2026 in April 2026.

•

As of April 30, 2026, the first 23 patients in Cohort 2 have had the opportunity for at least 60 weeks of follow-up since beginning treatment. By late 2026, all 46 patients in Cohort 2 will have had the opportunity for at least 60 weeks of follow-up since beginning treatment.

•

We believe our clinical data package positions us for meaningful regulatory engagement in 2026 to align on the path forward.

•

As of April 30, 2026, a total of 20 patients have been treated in Cohort 3. This cohort is now closed to enrollment. By late 2026, the eight patients initially enrolled for dose-limiting toxicity (DLT) assessment will have had the opportunity for at least 48 weeks of follow-up since beginning treatment.

•

Cohort 4 is now open for recruitment.

•

During the dose-finding phase of the study, we enrolled primarily NET patients whose disease originated in the pancreas or the digestive tract. We have an allowance for enrollment of NET patients whose disease originated in the lung (of which small cell lung cancer is a subset), pheochromocytoma/paraganglioma NETs, and SSTR2+ meningioma.

•

We opened a proof-of-concept cohort of meningioma patients. To date, there is no approved systematic therapy for this disease. The unmet medical need may support an expedited development path.

VMT01

VMT01 is an MC1R-targeted RPT that can be radiolabeled with either 203Pb for patient selection and dosimetry assessment or 212Pb for alpha-particle therapy. We are conducting a multi-center, open-label, dose-finding study (clinicaltrials.gov identifier NCT05655312) in heavily pre-treated patients with histologically confirmed melanoma and MC1R-positive imaging scans.

•

Since dosing re-opened for 3.0 mCi of VMT01 as monotherapy, and was initiated for 3.0 mCi of VMT01 in combination with nivolumab in September 2025, 10 patients had received VMT01 3.0 mCi treatment as of February 28, 2026; six patients had received VMT01 at 3.0 mCi in combination with nivolumab, and four patients had received 3.0 mCi of VMT01 as monotherapy, in addition to the three patients who received this monotherapy dose in late 2023. Both cohorts are now closed for enrollment.

•

By late 2026, the 10 patients who had received VMT01 3.0 mCi treatment since the initiation or re-opening of these cohorts in September 2025 will have had the opportunity for at least 24 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to three doses every eight weeks).

PSV359

We designed PSV359 to target and deliver 212Pb to tumor sites expressing fibroblast activation protein-α (FAP-α), which is associated with multiple highly prevalent solid tumors, in patients in need of additional treatment options.

•

As of April 30, 2026, two patients in Cohort 1 had been treated with [212Pb]PSV359 at 2.5 mCi, and seven patients in Cohort 2 had been treated at 5.0 mCi, for a total of nine patients. By late 2026, these patients will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to four doses every eight weeks).

•

Cohort 3 is now open for recruitment.

Updates to the preclinical pipeline

Our discovery team is preparing additional novel constructs for potential first-in-human (FIH) imaging.

•

In May 2026, we presented an FIH image for PSV594, designed to target and deliver 212Pb to tumor sites expressing the Cholecystokinin 2 Receptor (CCK2R), which is expressed across a range of hard-to-treat cancers. The targeting moiety may also be radiolabeled with 203Pb or 68Ga to detect CCK2R expression in-vivo. Preclinical and FIH images suggest the targeting moiety has clean, precise tumor uptake with limited kidney retention, which may result in a desirable therapeutic index.

Updates on manufacturing infrastructure

We continue to make progress on expanding our manufacturing capabilities by increasing and enhancing capacity at existing facilities and building out recently acquired sites.

•

Our flagship site in the Chicago area is on track to complete construction this year. We are building a complementary site in the Los Angeles area and have plans beyond our current footprint.

First Quarter 2026 Financial Summary

Cash, cash equivalents, and short-term investments as of March 31, 2026, were approximately $271 million as compared to $145 million as of December 31, 2025. In February 2026, we announced the closing of an underwritten offering of securities with net proceeds of approximately $164 million after deducting underwriting discounts and commissions and other offering-related expenses. We believe our cash, cash equivalents, and short-term investments as of March 31, 2026, will be sufficient to fund our current clinical milestones and operational investments into late 2027.

As of March 31, 2026, we had approximately 114.0 million shares of common stock and approximately 20.5 million warrants and options to purchase shares of common stock outstanding. In connection with the February 2026 underwritten offering of securities noted above, we issued 39.6 million shares of common stock along with pre-funded warrants to purchase 6.6 million shares of common stock.

Research and development expenses were $21.4 million for the three months ended March 31, 2026, compared to $14.3 million for the three months ended March 31, 2025, an increase of approximately 50%. The increase in research and development expenses was primarily related to higher personnel costs, including share-based compensation, due to additional headcount to support our ongoing clinical trials, as well as increased spending on contract development and manufacturing organizations, clinical site activities, drug programs and delivery, pipeline studies and consulting.

General and administrative expenses were $7.0 million for the three months ended March 31, 2026, compared to $7.8 million for the three months ended March 31, 2025, a decrease of approximately 10%. The decrease in general and administrative expenses was primarily due to decreased fees for professional and consulting services and fees related to operating as a public company, partially offset by increased personnel costs.

Net loss for the three months ended March 31, 2026, was $26.2 million, or $0.25 per basic and diluted share, compared to a net loss of $18.2 million, or $0.25 per basic and diluted share, for the same period in 2025. During the three months ended March 31, 2026 and 2025, there was a net benefit of $2.1 million and $2.3 million, respectively, in net interest income and other expenses. In addition, during the three months ended March 31, 2025 we recognized $1.4 million of Deferred Income, which was received in 2024.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company's expectations regarding cash runway; the Company’s manufacturing, distribution and commercialization plans and capabilities; the Company’s clinical and preclinical development plans and the expected timing for the release of additional data from its development programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates, the Company’s interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s preclinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contact:

Perspective Therapeutics IR:

Annie J. Cheng, CFA

ir@perspectivetherapeutics.com

ENTENTE Network of Companies

Virginia Amann

virginiaamann@ententeinc.com

Perspective Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except shares and par value data)

March 31,

December 31,

2026

2025

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

53,972

30,629

Short-term investments

216,957

114,108

Accounts receivable, net (allowance for doubtful accounts was $375 for each period)

Prepaid expenses and other current assets

4,365

3,646

Total current assets

275,352

148,389

Noncurrent assets:

Property and equipment, net

92,483

76,597

Right of use asset, net

2,444

1,500

Intangible assets, in-process research and development

40,000

Other assets, net

490

486

Total assets

410,769

266,972

LIABILITIES AND STOCKHOLDERSʼ EQUITY

Current liabilities:

Accounts payable and accrued expenses

26,485

20,511

Lease liability

1,069

623

Accrued personnel expenses

3,876

7,489

Note payable

Total current liabilities

31,486

28,679

Noncurrent liabilities:

Lease liability, net of current portion

1,552

1,005

Note payable, net of current portion

1,554

1,569

Deferred Income

26,600

Deferred tax liability

1,702

Other noncurrent liabilities

437

386

Total liabilities

63,331

59,941

Commitments and contingencies

Stockholdersʼ equity:

Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued

Common stock: $0.001 par value; 750,000,000 shares authorized; 114,017,755 and 74,337,990 shares issued

114

Additional paid-in capital

708,579

541,687

Accumulated other comprehensive (loss) income

(226

)

110

Accumulated deficit

(361,029

)

(334,840

)

Total stockholdersʼ equity

347,438

207,031

Total liabilities and stockholdersʼ equity

410,769

266,972

Perspective Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(Dollars and shares in thousands, except for per-share amounts)

Three Months Ended March 31,

2026

2025

Grant revenue

342

Operating expenses:

Research and development

21,372

14,332

General and administrative

6,985

7,842

Total operating expenses

28,357

22,174

Operating loss

(28,281

)

(21,832

)

Non-operating income (expense):

Interest income

2,197

2,384

Interest and other expense

(105

)

(128

)

Other income from a related party

1,400

Equity in loss of affiliate

)

Total non-operating income, net

2,092

3,655

Net loss

(26,189

)

(18,177

)

Basic and diluted loss per share

(0.25

)

(0.25

)

Weighted average shares used in computing net loss per share:

Basic and diluted

103,604

72,357

Unrealized (loss) gain on available-for-sale securities

(336

)

Comprehensive loss

(26,525

)

(18,107

)

EX-99.2

Filename: catx-ex99_2.htm · Sequence: 3

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Engineering the Alpha Advantage in Targeted Oncology

Unlocking New Treatment Options Across Solid Tumors:

Optimizing the Entire System

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Optimizing Structural Chemistry:

Choosing The Right Isotope

Not All ²¹²Pb Programs Are Created Equal

Advancing a Theranostic Approach:

Solid Tumors are an Attractive Market for Radiopharmaceuticals

Expanding the Addressable Market

Direct-to-Hospital Delivery through Integrated Isotope Production

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

Reaching the Largest Addressable Market with Regional Manufacturing

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

VMT-⍺-NET: Baseline Patient Characteristics in AACR 2026 Data Analysis

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in AACR 2026 Data Analysis

VMT-α-NET Responses Deepen Over Time

VMT-⍺-NET: Durable Disease Control Across All Doses

Spider Plot of Tumor Change Over Time by Patient

Best-in-class Safety Profile1

Blood Creatinine During Follow-up for All Patients Treated (n=64)

VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

A Decade of Deliberate, End-to-End Engineering

Built Over a Decade:

Abbreviations

APPENDIX

NETs Trials

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Refractory Metastatic Melanoma Trials

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

Construct designed for better clinical outcome

212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors

GRAPHIC

Filename: img236230851_0.jpg · Sequence: 4

Binary file (52710 bytes)

Download img236230851_0.jpg

GRAPHIC

Filename: catx-ex99_2s1.jpg · Sequence: 5

Binary file (157625 bytes)

Download catx-ex99_2s1.jpg

GRAPHIC

Filename: catx-ex99_2s2.jpg · Sequence: 6

Binary file (536297 bytes)

Download catx-ex99_2s2.jpg

GRAPHIC

Filename: catx-ex99_2s3.jpg · Sequence: 7

Binary file (279621 bytes)

Download catx-ex99_2s3.jpg

GRAPHIC

Filename: catx-ex99_2s4.jpg · Sequence: 8

Binary file (222440 bytes)

Download catx-ex99_2s4.jpg

GRAPHIC

Filename: catx-ex99_2s5.jpg · Sequence: 9

Binary file (275005 bytes)

Download catx-ex99_2s5.jpg

GRAPHIC

Filename: catx-ex99_2s6.jpg · Sequence: 10

Binary file (272290 bytes)

Download catx-ex99_2s6.jpg

GRAPHIC

Filename: catx-ex99_2s7.jpg · Sequence: 11

Binary file (253018 bytes)

Download catx-ex99_2s7.jpg

GRAPHIC

Filename: catx-ex99_2s8.jpg · Sequence: 12

Binary file (240312 bytes)

Download catx-ex99_2s8.jpg

GRAPHIC

Filename: catx-ex99_2s9.jpg · Sequence: 13

Binary file (269643 bytes)

Download catx-ex99_2s9.jpg

GRAPHIC

Filename: catx-ex99_2s10.jpg · Sequence: 14

Binary file (273025 bytes)

Download catx-ex99_2s10.jpg

GRAPHIC

Filename: catx-ex99_2s11.jpg · Sequence: 15

Binary file (209755 bytes)

Download catx-ex99_2s11.jpg

GRAPHIC

Filename: catx-ex99_2s12.jpg · Sequence: 16

Binary file (228254 bytes)

Download catx-ex99_2s12.jpg

GRAPHIC

Filename: catx-ex99_2s13.jpg · Sequence: 17

Binary file (291990 bytes)

Download catx-ex99_2s13.jpg

GRAPHIC

Filename: catx-ex99_2s14.jpg · Sequence: 18

Binary file (223483 bytes)

Download catx-ex99_2s14.jpg

GRAPHIC

Filename: catx-ex99_2s15.jpg · Sequence: 19

Binary file (274179 bytes)

Download catx-ex99_2s15.jpg

GRAPHIC

Filename: catx-ex99_2s16.jpg · Sequence: 20

Binary file (391608 bytes)

Download catx-ex99_2s16.jpg

GRAPHIC

Filename: catx-ex99_2s17.jpg · Sequence: 21

Binary file (251863 bytes)

Download catx-ex99_2s17.jpg

GRAPHIC

Filename: catx-ex99_2s18.jpg · Sequence: 22

Binary file (278622 bytes)

Download catx-ex99_2s18.jpg

GRAPHIC

Filename: catx-ex99_2s19.jpg · Sequence: 23

Binary file (246669 bytes)

Download catx-ex99_2s19.jpg

GRAPHIC

Filename: catx-ex99_2s20.jpg · Sequence: 24

Binary file (255239 bytes)

Download catx-ex99_2s20.jpg

GRAPHIC

Filename: catx-ex99_2s21.jpg · Sequence: 25

Binary file (286283 bytes)

Download catx-ex99_2s21.jpg

GRAPHIC

Filename: catx-ex99_2s22.jpg · Sequence: 26

Binary file (235572 bytes)

Download catx-ex99_2s22.jpg

GRAPHIC

Filename: catx-ex99_2s23.jpg · Sequence: 27

Binary file (220935 bytes)

Download catx-ex99_2s23.jpg

GRAPHIC

Filename: catx-ex99_2s24.jpg · Sequence: 28

Binary file (323273 bytes)

Download catx-ex99_2s24.jpg

GRAPHIC

Filename: catx-ex99_2s25.jpg · Sequence: 29

Binary file (278150 bytes)

Download catx-ex99_2s25.jpg

GRAPHIC

Filename: catx-ex99_2s26.jpg · Sequence: 30

Binary file (238430 bytes)

Download catx-ex99_2s26.jpg

GRAPHIC

Filename: catx-ex99_2s27.jpg · Sequence: 31

Binary file (202948 bytes)

Download catx-ex99_2s27.jpg

GRAPHIC

Filename: catx-ex99_2s28.jpg · Sequence: 32

Binary file (261360 bytes)

Download catx-ex99_2s28.jpg

GRAPHIC

Filename: catx-ex99_2s29.jpg · Sequence: 33

Binary file (263984 bytes)

Download catx-ex99_2s29.jpg

GRAPHIC

Filename: catx-ex99_2s30.jpg · Sequence: 34

Binary file (255728 bytes)

Download catx-ex99_2s30.jpg

GRAPHIC

Filename: catx-ex99_2s31.jpg · Sequence: 35

Binary file (236157 bytes)

Download catx-ex99_2s31.jpg

GRAPHIC

Filename: catx-ex99_2s32.jpg · Sequence: 36

Binary file (237246 bytes)

Download catx-ex99_2s32.jpg

GRAPHIC

Filename: catx-ex99_2s33.jpg · Sequence: 37

Binary file (222164 bytes)

Download catx-ex99_2s33.jpg

GRAPHIC

Filename: catx-ex99_2s34.jpg · Sequence: 38

Binary file (236687 bytes)

Download catx-ex99_2s34.jpg

GRAPHIC

Filename: catx-ex99_2s35.jpg · Sequence: 39

Binary file (258186 bytes)

Download catx-ex99_2s35.jpg

GRAPHIC

Filename: catx-ex99_2s36.jpg · Sequence: 40

Binary file (257268 bytes)

Download catx-ex99_2s36.jpg

GRAPHIC

Filename: catx-ex99_2s37.jpg · Sequence: 41

Binary file (207963 bytes)

Download catx-ex99_2s37.jpg

GRAPHIC

Filename: catx-ex99_2s38.jpg · Sequence: 42

Binary file (208384 bytes)

Download catx-ex99_2s38.jpg

GRAPHIC

Filename: catx-ex99_2s39.jpg · Sequence: 43

Binary file (166940 bytes)

Download catx-ex99_2s39.jpg

GRAPHIC

Filename: catx-ex99_2s40.jpg · Sequence: 44

Binary file (194255 bytes)

Download catx-ex99_2s40.jpg

GRAPHIC

Filename: catx-ex99_2s41.jpg · Sequence: 45

Binary file (278046 bytes)

Download catx-ex99_2s41.jpg

GRAPHIC

Filename: catx-ex99_2s42.jpg · Sequence: 46

Binary file (191995 bytes)

Download catx-ex99_2s42.jpg

GRAPHIC

Filename: catx-ex99_2s43.jpg · Sequence: 47

Binary file (99177 bytes)

Download catx-ex99_2s43.jpg

GRAPHIC

Filename: catx-ex99_2s44.jpg · Sequence: 48

Binary file (274199 bytes)

Download catx-ex99_2s44.jpg

GRAPHIC

Filename: catx-ex99_2s45.jpg · Sequence: 49

Binary file (86547 bytes)

Download catx-ex99_2s45.jpg

GRAPHIC

Filename: catx-ex99_2s46.jpg · Sequence: 50

Binary file (271555 bytes)

Download catx-ex99_2s46.jpg

GRAPHIC

Filename: catx-ex99_2s47.jpg · Sequence: 51

Binary file (340611 bytes)

Download catx-ex99_2s47.jpg

GRAPHIC

Filename: catx-ex99_2s48.jpg · Sequence: 52

Binary file (267682 bytes)

Download catx-ex99_2s48.jpg

GRAPHIC

Filename: catx-ex99_2s49.jpg · Sequence: 53

Binary file (304475 bytes)

Download catx-ex99_2s49.jpg

GRAPHIC

Filename: catx-ex99_2s50.jpg · Sequence: 54

Binary file (302519 bytes)

Download catx-ex99_2s50.jpg

GRAPHIC

Filename: catx-ex99_2s51.jpg · Sequence: 55

Binary file (251861 bytes)

Download catx-ex99_2s51.jpg

GRAPHIC

Filename: catx-ex99_2s52.jpg · Sequence: 56

Binary file (224835 bytes)

Download catx-ex99_2s52.jpg

GRAPHIC

Filename: catx-ex99_2s53.jpg · Sequence: 57

Binary file (301218 bytes)

Download catx-ex99_2s53.jpg

GRAPHIC

Filename: catx-ex99_2s54.jpg · Sequence: 58

Binary file (285039 bytes)

Download catx-ex99_2s54.jpg

GRAPHIC

Filename: catx-ex99_2s55.jpg · Sequence: 59

Binary file (231600 bytes)

Download catx-ex99_2s55.jpg

GRAPHIC

Filename: catx-ex99_2s56.jpg · Sequence: 60

Binary file (327499 bytes)

Download catx-ex99_2s56.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 63

v3.26.1

Document And Entity Information

May 11, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 11, 2026

Entity Registrant Name

Perspective Therapeutics, Inc.

Entity Central Index Key

0000728387

Entity Emerging Growth Company

false

Entity File Number

001-33407

Entity Incorporation, State or Country Code

Entity Tax Identification Number

41-1458152

Entity Address, Address Line One

c/o Perspective Therapeutics, Inc.

Entity Address, Address Line Two

2401 Elliott Avenue

Entity Address, Address Line Three

Suite 320

Entity Address, City or Town

Seattle

Entity Address, State or Province

Entity Address, Postal Zip Code

98121

City Area Code

(206)

Local Phone Number

676-0900

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

CATX

Security Exchange Name

NYSEAMER

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration